New insight into RASopathy-associated lymphatic defects

The RAS pathway is a cellular signaling pathway that regulates growth and development in humans. RASopathies are a group of diseases characterized by defects in RAS signaling.

Many patients with RASopathies present with defects in the lymphatic system, which removes excess fluid from tissues, absorbs fats from the digestive system, and transports immune cells.

To determine how alterations in the RAS pathway affect development of the lymphatic system, researchers at Yale University generated that expressed mutations associated with a RASopathy known as .

In this issue of the , Michael Simon and colleagues report that excess RAS pathway activation triggers increased activity of a protein known as ERK.

Mice with RASopathy-associated mutations exhibited lymphatic defects similar to those seen in humans, but the defects could be reversed by treatment with an ERK inhibitor.

These findings demonstrate that excessive ERK activation underlies lymphatic defects in RASopathies and suggest that ERK inhibition could be a useful therapeutic strategy.

More information: Endothelial ERK signaling controls lymphatic fate specification, Journal of Clinical Investigation, doi:10.1172/JCI63034

add to favorites email to friend print save as pdf

Related Stories

Lack of specific gene plays role in autism

Feb 09, 2009

It is estimated that three to six out of every 1,000 children in the United States have autism - and the number of diagnosed cases is rising. Autism is one of a group of series developmental problems called autism spectrum ...

Combination therapies for drug-resistant cancers

Oct 10, 2011

Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts ...

Recommended for you

User comments